Berberine
SupplementThe medical score is somewhat higher, as consistent RCT data and meta-analyses [s2, s3, s4] clearly support efficacy. The community reports more heterogeneous experiences with greater incidence of side effects and product quality issues [c1, c4, c5], which moderately dampens the community score.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Berberin is one of the best-evidenced botanical supplements for blood sugar and lipid control: over 27 RCTs with more than 3,500 participants show consistent reductions in HbA1c, LDL, and triglycerides, with one RCT demonstrating non-inferiority to metformin. However, the risk profile is non-trivial — hypoglycemia, QT prolongation, and interactions with anticoagulants require medical supervision, especially with co-medication. Critically, EFSA in 2026 could not establish a safe intake level, and a ban as a dietary supplement in the EU is a real possibility. Anyone using berberine should monitor the regulatory situation closely and never combine it unsupervised with antidiabetic drugs.
Description
Plant-derived alkaloid with documented blood glucose- and cholesterol-lowering effects via AMPK activation; EFSA safety assessment 2026 still pending [s1, s2, s14].
Berberine (BBR) is an isoquinoline alkaloid found in various medicinal plants, including Berberis vulgaris (barberry), Coptis chinensis, and Hydrastis canadensis (goldenseal). It has been used for centuries in traditional Chinese and Ayurvedic medicine [s1]. The most well-established pharmacological effects concern glucose and lipid metabolism. Multiple meta-analyses of RCTs demonstrate significant reductions in fasting blood glucose, HbA1c, LDL cholesterol, and triglycerides [s2, s3, s4]. A head-to-head comparison study showed that berberine can reduce glycemic parameters with similar efficacy to metformin [s5]. Oral bioavailability of berberine is very low (below 5%), attributable to pronounced first-pass metabolism and poor intestinal absorption [s7]. A large proportion of its pharmacological effect is therefore attributed to direct interaction with the gut microbiota [s8]. Berberine also demonstrates effects in polycystic ovary syndrome (PCOS) through improvement of insulin resistance and hormonal parameters [s9]. Cardiovascular effects include a possible antiarrhythmic action in ventricular extrasystoles, though with a theoretical risk of QT prolongation at high doses [s10, s11]. The EFSA has been reviewing the safety of berberine in botanical food supplements since 2022. In January 2026, a draft opinion was published concluding that a safe intake level for berberine could not be established [s13, s14]. EU-wide regulation remains unresolved as of 2026.
Legal Status (DE)
In Germany and the EU, the status of berberine as a food supplement is uncertain. In its draft opinion of 29 January 2026, the EFSA concluded that a safe intake level could not be determined and continues to review its safety [s14]. The German Consumer Advice Centre (Verbraucherzentrale) states clearly: "In the EU, berberine itself may not be sold as a food supplement" [s14]. Products are, however, still factually available on the market. The legal status is currently in flux, and a final EU decision is expected in 2026 [s13]. Comparable regulations apply in Switzerland and Austria. Consumers should verify the current legal situation before purchasing.
Mechanism of Action
The primary mechanism of berberine is activation of AMP-activated protein kinase (AMPK) [s1, s2]. AMPK is a central cellular energy sensor; its activation promotes glucose uptake in muscle and adipose tissue (via GLUT4 translocation), inhibits hepatic gluconeogenesis, and promotes fatty acid oxidation [s1, s2]. Berberine activates AMPK indirectly by inhibiting mitochondrial electron transport chain complex I, thereby raising the intracellular AMP/ATP ratio and triggering AMPK phosphorylation at Thr-172 [s6]. This mechanism is analogous to that of metformin [s2]. Additional mechanisms include: - Inhibition of intestinal glucose absorption via reduction of disaccharidase activity [s2] - Upregulation of insulin receptors and improvement of insulin sensitivity [s2] - Inhibition of hepatic cholesterol synthesis and upregulation of the LDL receptor (LDLR), analogous to statins but via a distinct pathway [s4] - Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), enhancing LDL catabolism [s4] - Modulation of gut microbiota: berberine alters the composition of the intestinal microbiota, potentially amplifying metabolic effects [s8] - Anti-inflammatory effects via AMPK-dependent inhibition of pro-inflammatory signaling pathways in macrophages [s12]
Dosing
Blutzuckerkontrolle / Typ-2-Diabetes
- Dose
- 500 mg per dose, 3× daily
- Frequency
- 3× täglich (1.500 mg/Tag gesamt)
- Route
- oral
- Duration
- 12–24 Wochen
- Timing
- 15–30 minutes before meals
- With food
- vermeiden
Dyslipidämie / LDL-Senkung
- Dose
- 500 mg per dose, 2× daily
- Frequency
- 2× täglich (1.000 mg/Tag gesamt)
- Route
- oral
- Duration
- 8–12 Wochen
- Timing
- With meals
- With food
- empfohlen
PCOS / Insulinresistenz
- Dose
- 500 mg per dose, 3× daily
- Frequency
- 3× täglich (1.500 mg/Tag gesamt)
- Route
- oral
- Duration
- 12–24 Wochen
- Timing
- With meals
- With food
- empfohlen
Doses of up to 1,500 mg/day have been used in clinical studies [s2, s5]. The EFSA did not establish a safe intake level in 2026 [s13, s14]. Cyclic use (e.g., 8 weeks on, 4 weeks off) is recommended by some experts to minimize potential effects on gut microbiota [s8]. High-dose protocols exceeding 1,500 mg/day are not supported by clinical data and should be avoided.
Due to low bioavailability (<5%), split dosing across 2–3 daily administrations is recommended to achieve more consistent plasma levels [s7]. Starting with 500 mg/day and gradually increasing the dose reduces gastrointestinal side effects [s2].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Durchfall, Bauchkrämpfe, Verstopfung) The most common adverse effect in RCTs; results from high intestinal berberine concentration with low systemic bioavailability [s7]. Documented as the most frequently reported adverse effect in meta-analyses [s2]. | häufig | leicht |
| Hypoglykämie (starke Blutzuckersenkung) Particularly with concurrent use of antidiabetic agents or in pre-diabetics without medical supervision. Individual case reports of severe hypoglycemia (BG < 40 mg/dL) documented in the community [c4]. | gelegentlich | moderat |
| Verlängerung des QT-Intervalls (theoretisches Arrhythmierisiko) Berberine inhibits the hERG channel (IKr), which is responsible for cardiac repolarization. No significant clinical QT effect was observed in meta-analyses on ventricular extrasystoles [s10]; however, caution is warranted at high doses or in predisposed individuals [s11]. | theoretisch | schwer |
| Veränderung der Darmmikrobiota Berberine has antimicrobial properties and may alter gut microbiota composition with long-term use. Clinical relevance is unclear [s8]. | gelegentlich | leicht |
| Hepatotoxizität The 2026 EFSA safety assessment found evidence of hepatic stress in animal studies. Rare in humans, but possible in combination with other hepatotoxic substances [s13]. | selten | schwer |
Contraindications
Berberine can cross the placental barrier and is associated with kernicterus (hyperbilirubinemia) in neonates. During lactation, berberine is excreted into breast milk. Contraindicated [s15].
Safety data in children are largely lacking. Berberine can affect bilirubin metabolism and cause kernicterus in neonates [s15].
Berberine metabolism and excretion are altered in impaired hepatic or renal function. Increased risk of accumulation and toxicity [s15].
Berberine inhibits the hERG channel and may theoretically prolong the QT interval. Increased arrhythmia risk in pre-existing long QT syndrome or with concomitant use of QT-prolonging medications [s11].
Berberine inhibits CYP3A4, CYP2D6, and CYP2C9, potentially leading to elevated plasma concentrations of numerous medications. Medical consultation required before combining with prescription drugs [s15].
Interactions
Synergistic
Additive blood glucose-lowering effect via similar AMPK mechanism. Combination may help reduce metformin dose, but requires close blood glucose monitoring due to hypoglycemia risk [s5].
Combination of berberine 500 mg/day with simvastatin 20 mg/day showed greater LDL reduction than either substance alone in one study [s4].
Berberine and alpha-lipoic acid both improve insulin sensitivity via partially independent signaling pathways. The combination can additively enhance cellular glucose uptake and is of particular interest in insulin resistance and diabetic neuropathy.
Berberine and curcumin exhibit synergistic anti-inflammatory and antioxidant effects in combination. In animal studies, the combination improved NAFLD parameters and jointly inhibited NF-κB as well as PI3K/AKT/mTOR signaling pathways more potently than either substance alone.
Berberine and inositol can be combined for PCOS-related insulin resistance, as they improve insulin sensitivity via different mechanisms. The combination may be particularly beneficial in women with PCOS who exhibit a disturbed myo/D-chiro-inositol balance.
Berberine and CoQ10 both activate AMPK and support mitochondrial function. A combination may synergistically improve cellular energy production and metabolic function.
Berberine and ashwagandha act on different systems and can complement each other beneficially. Berberine improves glucose and lipid metabolism, while ashwagandha lowers cortisol levels, thereby reducing cortisol-mediated gluconeogenesis.
Caution
Berberine inhibits CYP2C9, which metabolizes warfarin. Elevated bleeding risk possible due to increased anticoagulant plasma levels [s15].
Additive blood glucose-lowering effect; risk of hypoglycemia. Dose adjustment and blood glucose monitoring required [s2, s5].
Theoretical additive QT prolongation risk due to hERG channel inhibition by berberine in combination with other QT-prolonging substances [s11].
Berberine inhibits CYP3A4 and may increase plasma concentrations of CYP3A4 substrates. Particular caution warranted with narrow therapeutic windows [s15].
Both substances lower blood glucose and may increase hypoglycemia risk when taken concomitantly with antidiabetic agents. Individuals with diabetes should monitor blood glucose closely when using this combination.
Studies
Tier A — High Evidence
Outcome: Lipid profile: LDL-C, TC, TG, HDL-C, and obesity indices
Effect Size: Significant reduction in LDL-C, TC, TG; improvement in HDL-C and waist circumference
Outcome: LDL reduction as monotherapy and in combination with simvastatin
Effect Size: LDL -23.8% with berberine 500 mg 2×/day; additive effect with simvastatin
Outcome: Reproductive hormones, insulin resistance, and lipid profile in PCOS
Effect Size: Improvement in HOMA-IR, testosterone, SHBG, and lipid profile
Outcome: Reduction of HbA1c, fasting blood glucose, and postprandial blood glucose in type 2 diabetes
Effect Size: HbA1c −0.71% (vs. placebo); comparable to oral antidiabetic agents
Outcome: Head-to-head comparison of berberine vs. metformin: HbA1c, FBG, PBG, lipids
Effect Size: Non-inferior HbA1c reduction compared to metformin; more favorable lipid effects
Tier B — Moderate Evidence
Outcome: Effect on gut microbiota and metabolic parameters in type 2 diabetes
Effect Size: Gut microbiota changes correlate with glycemic control
Outcome: Efficacy and safety of berberine in ventricular extrasystoles
Effect Size: Efficacy against extrasystoles; no significant QT effect in controlled studies
Tier C — Low Evidence
Outcome: Anti-inflammatory effect via AMPK activation in macrophages
Effect Size: Inhibition of pro-inflammatory cytokines in macrophage cell culture
Outcome: Mechanism: inhibition of mitochondrial complex I, AMPK activation
Effect Size: AMPK phosphorylation demonstrated in 3T3-L1 adipocytes and L6 myotubes
Community Evidence
Top reported benefits
- Reduction of fasting blood glucose (reported after 4–8 weeks)
- Reduction of triglycerides
- Moderate weight loss in conjunction with dietary changes
- Improvement in energy levels and mood (occasional reports)
- Cost-effective alternative to metformin for pre-diabetics
Top reported issues
- Severe gastrointestinal complaints (diarrhea, cramps) when taken without a meal
- Hypoglycemic episodes, particularly in combination with antidiabetic agents
- Quality variations between different brands
- Long-term side effects after months of use (digestive issues)
- Uncertainty due to EFSA regulation and impending sales bans in the EU
Several Reddit users report sometimes severe hypoglycemic episodes, in some cases below 40 mg/dL, when combining berberine with other glucose-lowering interventions [c4]. Additionally, concerns exist regarding the regulatory future of berberine in the EU, as the EFSA was unable to establish a safe intake level in January 2026 and a sales ban as a food supplement appears possible [c5, s14]. Quality and berberine content vary considerably between suppliers.
Scientific Sources
- Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States
Lee YS, Kim WS, Kim KH, et al. (2006). Diabetes (American Diabetes Association)CPMID:16873688DOI - Efficacy and safety of berberine for premature ventricular contractions: a meta-analysis and systematic review of randomized controlled trials
Zhu X, Bian H, Wang L, et al. (2023). Pharmaceutical BiologyADOI - Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Ye Y, Liu X, Wu N, et al. (2021). TheranosticsBPMID:33042273DOI - Berberine suppresses proinflammatory responses through AMPK activation in macrophages
Jeong HW, Hsu KC, Lee JW, et al. (2009). American Journal of Physiology - Endocrinology and MetabolismCPMID:19116375DOI - European supplement regulations to watch in 2026 – EFSA berberine safety assessment
NutraIngredients Editorial (2026). NutraIngredientsBLink - Berberin zum Abnehmen? – Verbraucherzentrale Deutschland
Verbraucherzentrale Deutschland (2026). Verbraucherzentrale.deBLink - When to Avoid Berberine – Essential Safety Guide
Tonum Health Editorial (2024). Tonum.comCLink - Repeated administration of berberine inhibits cytochromes P450 in humans
Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH (2012). European Journal of Clinical PharmacologyAPMID:21870106DOI - Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Lan J, Zhao Y, Dong F, et al. (2022). Frontiers in PharmacologyAPMID:36386197DOI - The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis
Asbaghi O, Ghanbari N, Shekari M, et al. (2023). Complementary Therapies in Clinical PracticeAPMID:36724598DOI - Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review
Pirillo A, Catapano AL (2015). Evidence-Based Complementary and Alternative MedicineAPMID:25861268DOI - Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus
Yin J, Xing H, Ye J (2008). MetabolismAPMID:18442638DOI - Effects and mechanisms of berberine in diabetes treatment
Dong H, Wang N, Zhao L, et al. (2012). Oxidative Medicine and Cellular LongevityBPMID:22645638DOI - Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine
Cao C, Su M (2021). Journal of Traditional and Complementary MedicineBPMID:nullDOI - Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
Zhang Y, Gu Y, Ren H, et al. (2020). Nature CommunicationsAPMID:33004797DOI - Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study
Trolle B, Flyvbjerg A, Kesmodel US, et al. (2022). Frontiers in EndocrinologyAPMID:35299968DOI
Community Sources
Storage
Unopened
Store in a cool, dry place (below 25 °C), protected from direct sunlight and moisture.
Opened
Keep container tightly closed; powder formulations should be protected particularly from moisture, as berberine is hygroscopic.
Notes
Berberine has an intense yellow color and can permanently stain clothing and containers. Shelf life is typically 2–3 years with proper storage.